US-based clinical research organisation (CRO) TKL Research is adding to its cluster of research clinics in northern New Jersey with the construction of a new facility in Fair Lawn, which will include a 30-bed unit for Phase I trials.
The Fair Lawn facility, which will also feature multiple outpatient clinical-examination rooms, is expected to be operational early next year.
It will boost TKL Research’s specialist capabilities in dermatological safety studies while complementing the company’s Clinical Trials Division, based in Rochelle Park, New Jersey.
That Division provides full-service management of international multicentre studies in Phases II to IV.
The new unit in Fair Lawn will join three existing TKL Research clinics in the northern New Jersey area as part of the company’s Research Clinics Division.
In addition to its dermatology focus, TKL Research offers “deep” expertise in gastroenterology, respiratory, endocrinology and women’s health, the company noted.
TKL’s full range of clinical-trial management services extends from strategy and protocol development to biostatistics, medical writing and regulatory submission.
Founded more than 60 years ago, TKL Research moved its clinical research operations to Rochelle Park in 2006 and raised its European profile in 2010 by acquiring an equity stake in proinnovera, a full-service CRO with headquarters in Münster, Germany.